A Study for Participants With Advanced Cancer

• Status: Completed
• Trial end date: 2012-05-01

Summary

This study is being conducted to determine the safety of LY2523355 for the treatment of advanced and/or metastatic cancer (including Non-Hodgkin's lymphoma).

• Phase: Phase 1

Details

• Lead Sponsor: Eli Lilly and Company